Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2002 2
2003 4
2004 5
2005 2
2006 1
2007 7
2008 11
2009 9
2010 11
2011 10
2012 21
2013 12
2014 19
2015 6
2016 8
2017 7
2018 4
2019 6
2020 4
2021 7
2022 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

139 results
Results by year
Filters applied: . Clear all
Page 1
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T. Keyaerts M, et al. Among authors: lahoutte t. J Nucl Med. 2016 Jan;57(1):27-33. doi: 10.2967/jnumed.115.162024. Epub 2015 Oct 8. J Nucl Med. 2016. PMID: 26449837 Free article. Clinical Trial.
Immuno-imaging using nanobodies.
Vaneycken I, D'huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, Caveliers V, Lahoutte T. Vaneycken I, et al. Among authors: lahoutte t. Curr Opin Biotechnol. 2011 Dec;22(6):877-81. doi: 10.1016/j.copbio.2011.06.009. Epub 2011 Jul 2. Curr Opin Biotechnol. 2011. PMID: 21726996 Review.
Immunogenicity Risk Profile of Nanobodies.
Ackaert C, Smiejkowska N, Xavier C, Sterckx YGJ, Denies S, Stijlemans B, Elkrim Y, Devoogdt N, Caveliers V, Lahoutte T, Muyldermans S, Breckpot K, Keyaerts M. Ackaert C, et al. Among authors: lahoutte t. Front Immunol. 2021 Mar 9;12:632687. doi: 10.3389/fimmu.2021.632687. eCollection 2021. Front Immunol. 2021. PMID: 33767701 Free PMC article.
Bioluminescence imaging: looking beyond the light.
Keyaerts M, Caveliers V, Lahoutte T. Keyaerts M, et al. Among authors: lahoutte t. Trends Mol Med. 2012 Mar;18(3):164-72. doi: 10.1016/j.molmed.2012.01.005. Epub 2012 Feb 8. Trends Mol Med. 2012. PMID: 22321645 Review.
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy.
Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, De Veirman K, Vanderkerken K, Lahoutte T, Morgenstern A, Bruchertseifer F, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Among authors: lahoutte t. Mol Cancer Ther. 2022 Jan;21(1):159-169. doi: 10.1158/1535-7163.MCT-21-0220. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667109 Free PMC article.
139 results